{"hands_on_practices": [{"introduction": "To effectively engineer biological systems, we often begin by creating simple mathematical models of their core processes. For CRISPR activation, the foundational event is the binding of the dCas9-sgRNA complex to its specific DNA target. This exercise asks you to model this crucial interaction as a reversible chemical reaction, allowing you to connect a fundamental biophysical parameter, the dissociation constant ($K_d$), to a key outcome: the fraction of target sites occupied at equilibrium [@problem_id:2028453]. Understanding this relationship is vital for predicting how system parameters, like protein concentration and binding affinity, influence the potential for gene activation.", "problem": "A synthetic biologist is studying a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) activation (CRISPRa) system in a eukaryotic cell line. The system utilizes a deactivated Cas9 (dCas9) protein fused to a transcriptional activator. A single guide RNA (sgRNA) directs this dCas9-activator fusion protein to bind to a specific DNA sequence, the \"target site,\" located upstream of a gene's promoter. For the purpose of modeling, we will refer to the complete dCas9-activator-sgRNA assembly as the \"complex\" ($C$).\n\nThe binding of one molecule of the complex to one target site ($D$) is a reversible process that reaches a dynamic equilibrium within the cell nucleus, forming a bound state ($CD$).\n$$ C + D \\rightleftharpoons CD $$\nA researcher has engineered cells where the total concentration of the complex is maintained at $[C]_{\\text{total}} = 50.0$ nM, and the total concentration of available target sites on the genome is $[D]_{\\text{total}} = 2.00$ nM. The binding interaction is characterized by a dissociation constant, $K_d = 20.0$ nM.\n\nThe degree of gene activation is directly proportional to the fraction of target sites occupied by the complex at equilibrium. Assuming that the total concentration of the complex is significantly larger than the total concentration of target sites, calculate the fraction of occupied target sites under these equilibrium conditions.\n\nExpress your answer as a decimal rounded to three significant figures.", "solution": "We consider the reversible binding reaction $C + D \\rightleftharpoons CD$ at equilibrium. By the law of mass action, the dissociation constant is\n$$\nK_{d} = \\frac{[C][D]}{[CD]}.\n$$\nConservation of target sites gives\n$$\n[D]_{\\text{total}} = [D] + [CD].\n$$\nThe fraction of occupied target sites is\n$$\nf = \\frac{[CD]}{[D]_{\\text{total}}}.\n$$\nSolve for $[CD]$ in terms of $[C]$ using the definition of $K_{d}$ and conservation. From $K_{d} = \\frac{[C][D]}{[CD]}$ and $[D] = [D]_{\\text{total}} - [CD]$, we have\n$$\nK_{d} = \\frac{[C]\\left([D]_{\\text{total}} - [CD]\\right)}{[CD]} \\;\\;\\Rightarrow\\;\\; K_{d}[CD] = [C][D]_{\\text{total}} - [C][CD].\n$$\nRearranging,\n$$\n[CD]\\left(K_{d} + [C]\\right) = [C][D]_{\\text{total}} \\;\\;\\Rightarrow\\;\\; [CD] = \\frac{[C][D]_{\\text{total}}}{K_{d} + [C]}.\n$$\nTherefore the fraction occupancy is\n$$\nf = \\frac{[CD]}{[D]_{\\text{total}}} = \\frac{[C]}{K_{d} + [C]}.\n$$\nAssuming $[C]_{\\text{total}} \\gg [D]_{\\text{total}}$, the free complex concentration satisfies $[C] \\approx [C]_{\\text{total}}$. Substituting the given values,\n$$\nf \\approx \\frac{[C]_{\\text{total}}}{K_{d} + [C]_{\\text{total}}} = \\frac{50.0}{20.0 + 50.0} = \\frac{50.0}{70.0} = \\frac{5}{7} \\approx 0.7142857\\ldots\n$$\nRounded to three significant figures, the fraction of occupied target sites is $0.714$.", "answer": "$$\\boxed{0.714}$$", "id": "2028453"}, {"introduction": "After modeling a system's theoretical potential, the next step is to measure its performance in a real biological context. This practice transitions from theory to application by demonstrating how to quantify the success of a CRISPRa experiment. You will work with raw data from a Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR) experiment, the gold-standard method for measuring gene expression levels [@problem_id:2028448]. By applying the comparative $C_q$ (or $\\Delta\\Delta C_q$) method, you will learn to calculate the fold-change in gene expression, a critical skill for validating any gene regulation technology.", "problem": "A researcher in a synthetic biology lab is attempting to increase the expression of a neurogenic transcription factor, `NEUROG2`, in a population of stem cells. To achieve this, they are using a CRISPR activation (CRISPRa) system. This system consists of a catalytically deactivated Cas9 (dCas9) protein fused to a transcriptional activation domain, which is directed to the promoter region of the `NEUROG2` gene by a specific guide RNA (gRNA).\n\nTo quantify the effectiveness of the CRISPRa system, the researcher performs an experiment with two conditions:\n1.  **Control Group**: Stem cells are treated with the dCas9-activator and a non-targeting gRNA that does not bind to the human genome.\n2.  **Experimental Group**: Stem cells are treated with the dCas9-activator and a gRNA specifically designed to target the promoter of the `NEUROG2` gene.\n\nAfter 48 hours, messenger RNA (mRNA) was extracted from both groups, and gene expression levels were measured using Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR). This technique measures the number of cycles required for the fluorescent signal to cross a threshold in a PCR reaction, a value known as the Quantification Cycle (Cq). A lower Cq value corresponds to a higher initial amount of template mRNA. To normalize the data, the expression of a stable housekeeping gene, `GAPDH`, was also measured in all samples. The experiment was performed with three technical replicates for each condition.\n\nThe recorded Cq values are as follows:\n\n**Control Group (Non-targeting gRNA):**\n-   `NEUROG2` Cq values: 28.5, 28.3, 28.7\n-   `GAPDH` Cq values: 21.1, 21.3, 21.2\n\n**Experimental Group (CRISPRa for `NEUROG2`):**\n-   `NEUROG2` Cq values: 24.2, 24.0, 24.4\n-   `GAPDH` Cq values: 21.2, 21.4, 21.3\n\nAssume that the amplification efficiency for both the `NEUROG2` and `GAPDH` primer sets is 100%. Calculate the fold change in `NEUROG2` mRNA expression in the experimental group relative to the control group. Round your final answer to three significant figures.", "solution": "We are asked for the fold change in target mRNA using RT-qPCR with 100 percent amplification efficiency. Under this assumption, the relative expression ratio is computed by the comparative Cq method:\n$$\n\\text{Fold change} = 2^{-\\Delta \\Delta \\mathrm{Cq}},\n$$\nwhere\n$$\n\\Delta \\mathrm{Cq} = \\mathrm{Cq}_{\\text{target}} - \\mathrm{Cq}_{\\text{reference}}, \\quad \\Delta \\Delta \\mathrm{Cq} = \\Delta \\mathrm{Cq}_{\\text{experimental}} - \\Delta \\mathrm{Cq}_{\\text{control}}.\n$$\n\nFirst compute the mean Cq values for each gene in each condition:\n$$\n\\overline{\\mathrm{Cq}}_{\\text{control, NEUROG2}} = \\frac{28.5+28.3+28.7}{3} = 28.5,\\quad\n\\overline{\\mathrm{Cq}}_{\\text{control, GAPDH}} = \\frac{21.1+21.3+21.2}{3} = 21.2,\n$$\n$$\n\\overline{\\mathrm{Cq}}_{\\text{experimental, NEUROG2}} = \\frac{24.2+24.0+24.4}{3} = 24.2,\\quad\n\\overline{\\mathrm{Cq}}_{\\text{experimental, GAPDH}} = \\frac{21.2+21.4+21.3}{3} = 21.3.\n$$\n\nCompute the normalized differences:\n$$\n\\Delta \\mathrm{Cq}_{\\text{control}} = 28.5 - 21.2 = 7.3, \\quad\n\\Delta \\mathrm{Cq}_{\\text{experimental}} = 24.2 - 21.3 = 2.9.\n$$\n\nThen\n$$\n\\Delta \\Delta \\mathrm{Cq} = 2.9 - 7.3 = -4.4.\n$$\n\nWith 100 percent efficiency, the fold change is\n$$\n\\text{Fold change} = 2^{-\\left(-4.4\\right)} = 2^{4.4} = 2^{4}\\cdot 2^{0.4} = 16 \\cdot \\exp\\!\\left(0.4 \\ln 2\\right) \\approx 16 \\cdot 1.3195 \\approx 21.1,\n$$\nwhich to three significant figures is $21.1$.", "answer": "$$\\boxed{21.1}$$", "id": "2028448"}, {"introduction": "Scientific research rarely proceeds without encountering obstacles. A key skill for any synthetic biologist is the ability to troubleshoot experiments that do not go as planned. This final practice places you in a realistic scenario where a CRISPRa experiment has failed to produce the desired gene activation [@problem_id:2028413]. By analyzing the results from a series of systematic diagnostic tests, you will learn to logically deduce the root cause of the problem, distinguishing between issues like poor protein expression, faulty guide RNA, or inaccessible chromatin.", "problem": "A synthetic biology research team is attempting to use a Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) activation (CRISPRa) system to upregulate a silent endogenous gene, `GENE-T`, in a human cell line. The system consists of two plasmids co-transfected into the cells: one expressing a nuclease-dead Cas9 (dCas9) protein fused to a potent tripartite transcriptional activator domain called VPR (VP64-p65-Rta), and another expressing a single guide RNA (`sgRNA-T`) designed to target the promoter region of `GENE-T`.\n\nAfter 48 hours, the researchers measure the mRNA levels of `GENE-T` using Reverse Transcription-quantitative Polymerase Chain Reaction (RT-qPCR) but observe no statistically significant increase compared to control cells that did not receive the `sgRNA-T` plasmid. To diagnose the problem, they perform a series of follow-up experiments:\n\n1.  **Activator Expression Check:** A Western blot is performed on lysates from the transfected cells using an antibody that recognizes the VPR domain. The result shows a distinct band at the correct molecular weight for the dCas9-VPR fusion protein, with an intensity comparable to a positive control sample known to work.\n\n2.  **System Functionality Control:** The team co-transfects cells with the same dCas9-VPR plasmid and a different sgRNA plasmid, `sgRNA-P`, which targets the promoter of `GENE-P`. `GENE-P` is a housekeeping gene known to reside in a region of open, accessible chromatin. This experiment results in a significant, 50-fold increase in `GENE-P` mRNA levels.\n\n3.  **Guide RNA Intrinsic Efficacy Test:** An *in vitro* binding assay is conducted. Purified dCas9-VPR protein is mixed with `sgRNA-T` and a short, synthetic, double-stranded DNA oligonucleotide containing the exact target sequence for `sgRNA-T` from the `GENE-T` promoter. Using an electrophoretic mobility shift assay (EMSA), they observe that the dCas9-VPR/sgRNA-T complex efficiently binds to the DNA oligonucleotide target, with a binding affinity in the low nanomolar range, which is considered highly effective.\n\nBased on the results of these three experiments, what is the most likely reason for the failure to activate `GENE-T` in the initial experiment?\n\nA. The dCas9-VPR activator protein was not successfully expressed in the cells.\n\nB. The `sgRNA-T` molecule is intrinsically unable to form a functional complex with the dCas9-VPR protein or to recognize its DNA target sequence.\n\nC. The chromatin structure at the `GENE-T` promoter is in a condensed, inaccessible state, preventing the CRISPRa complex from binding to its target site *in vivo*.\n\nD. The VPR activator domain of the dCas9-VPR fusion protein is non-functional and incapable of recruiting the transcription machinery.", "solution": "We evaluate each hypothesis against the provided experimental evidence using logical elimination.\n\nFirst, consider option A. The Western blot using an anti-VPR antibody shows a distinct band at the correct molecular weight for the dCas9-VPR fusion, with intensity comparable to a known positive control. This directly supports successful expression of the dCas9-VPR protein in cells, arguing against a failure of expression. Therefore, A is not consistent with the data.\n\nNext, consider option D. The system functionality control shows that co-transfection with the same dCas9-VPR plasmid and an alternative sgRNA, sgRNA-P, targeting an open-chromatin housekeeping gene promoter, yields a substantial activation (a 50-fold increase in mRNA). This demonstrates that the VPR activator domain is functional for recruiting transcriptional machinery in vivo and that the cellular context supports CRISPRa activity when targeting accessible loci. Therefore, D is not supported.\n\nThen, consider option B. The in vitro EMSA shows that the dCas9-VPR/sgRNA-T complex binds its exact DNA target with high affinity in the low nanomolar range, indicating that sgRNA-T is capable of forming a functional ribonucleoprotein complex and recognizing its target sequence. This rules out an intrinsic defect in sgRNA-Tâ€™s ability to bind dCas9 or its target DNA. Therefore, B is not supported.\n\nHaving excluded A, B, and D by direct evidence, the remaining explanation is that the CRISPRa complex cannot productively bind the target site in cells due to chromatin context. The lack of activation for GENE-T despite proper expression and functionality of dCas9-VPR and intrinsic competence of sgRNA-T is most consistent with inaccessible, condensed chromatin at the GENE-T promoter that prevents in vivo binding. This matches option C.\n\nTherefore, the most likely reason is that the chromatin at the GENE-T promoter is condensed and inaccessible, preventing CRISPRa binding and activation in vivo.", "answer": "$$\\boxed{C}$$", "id": "2028413"}]}